The Centers for Disease Control and Prevention (CDC) has recommended the use of Novavax’s COVID-19 vaccine for children ages 12-17 for primary series vaccination. See the CDC statement. This recommendation is in line with the FDA’s Emergency Use Authorization of the vaccine for this age group. A limited supply of Novavax is available for Health Center COVID-19 Vaccine Program participants. Health centers can make a one-time order of one package (100 doses) per health center site. See these CDC resources for more information:
- Novavax COVID-19 Vaccination Operational Planning Guide
- Use of COVID-19 Vaccines in the U.S. (This site was formerly called the “Interim Clinical Considerations for Use of COVID-19 Vaccines.”)